Bae Seong-Cheon, Noh He-Il, Jun Beom-Cho, Jeon Eun-Ju, Seo Jae-Hyun, Park So-Young, Kim Jun-Kyu, Lee Dong-Hee, Oh Jeong-Hoon, Park Shi-Nae, Yeo Sang-Won
Department of Otolaryngology-Head and Neck Surgery, College of Medicine, Catholic University of Korea, Seoul, Korea.
Acta Otolaryngol. 2013 May;133(5):428-33. doi: 10.3109/00016489.2012.749520. Epub 2013 Jan 28.
Intratympanic steroid therapy (IT-S) was as effective as systemic steroid therapy (SST) or combined therapy (CT) and could be considered a first-line therapeutic modality for idiopathic sudden sensorineural hearing loss (SSNHL). Due to its known safety and efficacy, IT-S will be particularly suitable for patients with SSNHL who have chronic diseases such as diabetes mellitus, hypertension, or chronic renal failure.
Systemic high dose steroid therapy is the main therapeutic modality for SSNHL. Comparable therapeutic efficacies for IT-S and CT with SST and IT-S for SSNHL have been reported recently. We compared the efficacy of IT-S, SST, and CT for treating SSNHL.
A retrospective, multicenter study investigating the therapeutic efficacy of SST, IT-S, and CT for SSNHL was designed and involved 735 patients with idiopathic SSNHL who were diagnosed and treated at seven tertiary referral medical centers of the Catholic University of Korea between 2007 and 2011. Patients were divided into three groups according to the treatment methods they received: IT-S group, SST group, and CT group (SS plus IT-S). Hearing was evaluated by pure tone audiogram performed before initial treatment and at 4 weeks following the final treatment. More than a 10 dB HL decrease in average air conduction threshold of hearing at 500, 1000, 2000, and 3000 Hz was defined as improved hearing.
Among 735 patients with SSNHL, 94 were included in the IT-S group, 444 in the SST, and 197 in the CT group. Age, gender, interval from disease onset to start of treatment, and initial hearing level were not different among the three groups. Patients who had concomitant medical disorders such as diabetes mellitus, hypertension, or chronic renal failure were more frequently treated with IT-S. No difference in the level of hearing gain or ratio of hearing improvement was observed among the three groups (p = 0.147 and p = 0.067, respectively).
鼓室内注射类固醇疗法(IT-S)与全身类固醇疗法(SST)或联合疗法(CT)效果相当,可被视为特发性突发性感音神经性听力损失(SSNHL)的一线治疗方式。鉴于其已知的安全性和有效性,IT-S尤其适用于患有糖尿病、高血压或慢性肾衰竭等慢性病的SSNHL患者。
全身大剂量类固醇疗法是SSNHL的主要治疗方式。最近有报道称IT-S和CT与SST治疗SSNHL的疗效相当。我们比较了IT-S、SST和CT治疗SSNHL的疗效。
设计了一项回顾性多中心研究,调查SST、IT-S和CT治疗SSNHL的疗效,研究对象为2007年至2011年期间在韩国天主教大学的7家三级转诊医疗中心诊断和治疗的735例特发性SSNHL患者。根据患者接受的治疗方法将其分为三组:IT-S组、SST组和CT组(SS加IT-S)。在初始治疗前和最终治疗后4周通过纯音听力图评估听力。500、1000、2000和3000Hz平均气导听力阈值下降超过10dB HL被定义为听力改善。
在735例SSNHL患者中,IT-S组94例,SST组444例,CT组197例。三组患者的年龄、性别、发病至开始治疗的间隔时间和初始听力水平无差异。患有糖尿病、高血压或慢性肾衰竭等合并症的患者更常接受IT-S治疗。三组之间的听力增益水平或听力改善率无差异(分别为p = 0.147和p = 0.067)。